Natrunix in HLA-B27 Positive Subjects With Axial Spondyloarthritis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 15, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

April 30, 2025

Conditions
Axial Spondyloarthritis
Interventions
DRUG

Natrunix

Natrunix is a monoclonal antibody preparation. Natrunix antibody is indistinguishable from a natural antibody isolated from a healthy human. Natrunix is expected to be the safest, most effective therapy for alleviating inflammatory pain and mitigating damage, mainly in the spine and sacroiliac joints, in AxSpA patients.

DRUG

Placebo

Placebo

All Listed Sponsors
lead

XBiotech, Inc.

INDUSTRY